Next 10 |
home / stock / meusw / meusw news
2024-05-23 19:44:09 ET 23andMe Holding Co. (ME) Q4 2024 Earnings Conference Call May 24, 2024 4:30 PM ET Company Participants Ian Cooney - Senior Director of Investor Relations Joe Selsavage - Chief Financial Officer and Chief Accounting Officer Anne Wojcicki - C...
2024-02-07 21:22:04 ET 23andMe Holding Co. (ME) Q3 2024 Earnings Conference Call February 07, 2024 04:30 PM ET Company Participants Ian Cooney - Senior Director of Investor Relations Anne Wojcicki - Co-Founder and Chief Executive Officer Joseph Selsavage - Interi...
2023-11-08 20:18:05 ET 23andMe Holding Co. (ME) Q2 2024 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Ian Cooney - Senior Director, IR Anne Wojcicki - Chief Executive Officer and Co-Founder Joseph Selsavage - Interim Chief Financial an...
2023-08-08 19:52:10 ET 23andMe Holding Co. (ME) Q1 2024 Results Conference Call August 08, 2023 04:30 PM ET Company Participants Katie Watson - Vice President of Communications Anne Wojcicki - Chief Executive Officer and Co-Founder Joe Selsavage - Interim Chief F...
2023-05-25 21:30:23 ET 23andMe Holding Co. (ME) Q4 2023 Results Conference Call May 25, 2023 04:30 PM ET Company Participants Maeve Conneighton - Investor Relations at Argo Partners Anne Wojcicki - Chief Executive Officer & Co-Founder Joe Selsavage - Interim ...
2023-04-03 08:55:13 ET Summary In December of 2022 I introduced a number of stocks which I was adding to my "Tax Loss Selling Basket". In this article I summarize the logic and criteria for the basket. I then tally up the results including calculating overall returns and looki...
2023-03-29 13:26:31 ET Summary 23andMe is known around the world for its ancestry DNA genetic testing service. The company's pivot into therapeutics seems attractive. But the company saw revenue decrease from $441 million in 2019 to $272 in 2022. What's the value of having...
2023-03-29 07:56:11 ET Summary GeneDx Holdings Corp. has had a dreadful performance as a stock. GeneDx's number of shares outstanding have absolutely exploded. GeneDx has a negative gross margin and is significantly burning cash. While its business model has merit, you nee...
23andMe Holding Co. (ME) Q3 2022 Earnings Conference Call Feb 08, 2023, 04:30 PM ET Company Participants Wade Walke - VP, Investor Relations Anne Wojcicki - CEO & Co-Founder Joe Selsavage - Interim CFO & Accounting Officer Kenneth Hillan - Chief Therapeutic...
Summary NVTA Q4 cash balance remained flat year-over-year at $555M, with 2022 revenue declining by $4M to $122M. Shares appreciated 25% after last week's Q4 purview on optimism over management's ability to trim operating costs, which would provide NVTA with sufficient runway to execute ...
News, Short Squeeze, Breakout and More Instantly...
23andMe Holding Co. Warrant Company Name:
MEUSW Stock Symbol:
NYSE Market:
23andMe Holding Co. Warrant Website: